Effectiveness of EGFR tyrosine kinase inhibitors in advanced non‐small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study

Background Epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) therapy is the standard treatment for advanced non‐small cell lung cancer (NSCLC) harboring common EGFR mutations, such as exon 19 deletion or L858 point mutation. However, the effectiveness of EGFR‐TKIs for patients wi...

詳細記述

書誌詳細

主要な著者:	Masaki Kanazu, Masahide Mori, Madoka Kimura, Kazumi Nishino, Takayuki Shiroyama, Izumi Nagatomo, Shoichi Ihara, Kiyoshi Komuta, Hidekazu Suzuki, Tomonori Hirashima, Toru Kumagai, Fumio Imamura
フォーマット:	Artigo
言語:	Inglês
出版事項:	Wiley 2021-01-01
シリーズ:	Thoracic Cancer
主題:	Afatinib epidermal growth factor receptor erlotinib gefitinib uncommon mutation
オンライン･アクセス:	https://doi.org/10.1111/1759-7714.13718
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!